![](/images/Company_Logo/company_logo_default.png)
Targazyme Inc (AKA: American Stem Cell Inc) Profile last edited on: 7/19/17
CAGE: 4CMG8
UEI: NJG4X7NZ4BM1
Business Identifier: Developing and commercializing products to improve immunotherapies Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
2100 Palomar Airport Road Suite 214-19
Carlsbad, CA 92011
Carlsbad, CA 92011
(760) 448-1168 |
info@targazyme.com |
www.americastemcell.com,www.targazyme.com |
Location: Multiple
Congr. District: 49
County: San Diego
Congr. District: 49
County: San Diego
Public Profile
Previously doing business as American Stem Cell Inc., Targazyme, Inc., a clinical-stage biopharmaceutical company, is engaged in developing and commercializing technologies and products that improve cell-based therapies and immunotherapies across a range of indications. With facailites in Texas and in Switerland, Targazyme offers ASC-101, a product for stem cell transplantation for hematological malignancies and for cell therapies of other cancer indications, as well as for ischemic diseases; ASC-102, a product for immune cell treatment for cancers; and Extracellular superoxide dismutase, an enzyme that destroys free radicals. The company's products applications include hematopoietic stem cell transplants, immunotherapies for solid tumors, cell therapies to ameliorate graft-versus-host and autoimmune diseases, and cell therapies for ischemic diseases, such as myocardial infarction and stroke. The company is based in Carlsbad, California with additional offices in San Diego, California; and Basel, Switzerland
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2016 | 2 | NIH | $1,526,626 | |
Project Title: A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD | ||||
2014 | 1 | NIH | $215,739 | |
Project Title: Novel Cell-Based Restorative Approach in Treatment of Diabetes-Related Retinopath | ||||
2014 | 1 | NIH | $224,932 | |
Project Title: Therapeutic Potential & Targeted Homing of Ecsod-Mscs in Animal Model of Mucositi | ||||
2013 | 1 | NIH | $335,440 | |
Project Title: Increased Therapeutic Potential Of Migrating Neural Stem Cells &Asc101 Treatment | ||||
2012 | 1 | NIH | $156,754 | |
Project Title: Asc101 Enhancement of Regenerative Capacity of Amniotic Fluid-Derived Stem Cells |
Key People / Management
Lynnet Koh -- Founder, President and Chief Executive Officer
Lynne A Bui
Bernard Cambou -- Chief Business Officer
Richard Martin -- Head of Operations and VP of Cmc
Leonard P Miller -- Vice President, Research/Co-Founder
Shah Rahimian -- VP of Clinical Development
William Jay Treat -- Co-Founder & VP Manufacturing
Alain Vertes -- VP Business Development EMEA and Asia
Lynne A Bui
Bernard Cambou -- Chief Business Officer
Richard Martin -- Head of Operations and VP of Cmc
Leonard P Miller -- Vice President, Research/Co-Founder
Shah Rahimian -- VP of Clinical Development
William Jay Treat -- Co-Founder & VP Manufacturing
Alain Vertes -- VP Business Development EMEA and Asia